TRACON Pharmaceuticals - TCON Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $60.00
  • Forecasted Upside: 8,990.91%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.66
▲ +0.03 (4.76%)

This chart shows the closing price for TCON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TRACON Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCON

Analyst Price Target is $60.00
▲ +8,990.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for TRACON Pharmaceuticals in the last 3 months. The average price target is $60.00, with a high forecast of $60.00 and a low forecast of $60.00. The average price target represents a 8,990.91% upside from the last price of $0.66.

This chart shows the closing price for TCON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in TRACON Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/1/2024HC WainwrightReiterated RatingBuy ➝ NeutralLow
4/3/2024HC WainwrightLower TargetBuy ➝ Buy$120.00 ➝ $60.00Low
3/6/2024HC WainwrightLower TargetBuy ➝ Buy$140.00 ➝ $120.00Low
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$140.00Low
8/21/2023JonestradingReiterated RatingBuy ➝ HoldLow
8/15/2023Robert W. BairdLower TargetOutperform ➝ Outperform$140.00 ➝ $60.00Low
5/11/2023Maxim GroupLower Target$160.00 ➝ $60.00Low
5/11/2023Robert W. BairdLower Target$160.00 ➝ $140.00Low
3/9/2023HC WainwrightReiterated RatingBuy$240.00Low
12/15/2022Robert W. BairdLower Target$200.00 ➝ $160.00Low
2/22/2022Robert W. BairdInitiated CoverageOutperform$200.00High
8/12/2021HC WainwrightReiterated RatingBuyLow
6/4/2021Alliance Global PartnersInitiated CoverageBuy$260.00High
4/16/2021BTIG ResearchUpgradeNeutral ➝ Buy$280.00High
4/1/2021JonestradingInitiated CoverageBuyLow
2/10/2021Maxim GroupInitiated CoverageBuy$480.00Low
12/4/2020HC WainwrightBoost TargetPositive ➝ Buy$140.00 ➝ $240.00High
9/17/2020HC WainwrightBoost TargetBuy$80.00 ➝ $140.00High
8/17/2020HC WainwrightReiterated RatingBuy$80.00High
4/24/2020HC WainwrightLower TargetBuy$120.00 ➝ $80.00Medium
3/10/2020HC WainwrightLower TargetBuy$260.00 ➝ $120.00High
2/28/2020HC WainwrightLower TargetBuy$360.00 ➝ $260.00High
1/17/2020HC WainwrightReiterated RatingBuy$360.00Medium
12/23/2019HC WainwrightBoost TargetBuy$300.00 ➝ $360.00Medium
11/7/2019HC WainwrightReiterated RatingBuy$40.00High
8/29/2019HC WainwrightInitiated CoverageBuy$40.00High
(Data available from 7/19/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/20/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
TRACON Pharmaceuticals logo
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.66
Low: $0.60
High: $0.66

50 Day Range

MA: $1.22
Low: $0.62
High: $2.02

52 Week Range

Now: $0.66
Low: $0.60
High: $14.75

Volume

8,034 shs

Average Volume

111,935 shs

Market Capitalization

$2.25 million

P/E Ratio

0.99

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of TRACON Pharmaceuticals?

The following equities research analysts have issued reports on TRACON Pharmaceuticals in the last twelve months: HC Wainwright, Jonestrading, Robert W. Baird, and StockNews.com.
View the latest analyst ratings for TCON.

What is the current price target for TRACON Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for TRACON Pharmaceuticals in the last year. Their average twelve-month price target is $60.00, suggesting a possible upside of 8,990.9%. Robert W. Baird has the highest price target set, predicting TCON will reach $60.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $60.00 for TRACON Pharmaceuticals in the next year.
View the latest price targets for TCON.

What is the current consensus analyst rating for TRACON Pharmaceuticals?

TRACON Pharmaceuticals currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TCON, but not buy more shares or sell existing shares.
View the latest ratings for TCON.

What other companies compete with TRACON Pharmaceuticals?

How do I contact TRACON Pharmaceuticals' investor relations team?

TRACON Pharmaceuticals' physical mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company's listed phone number is (858) 550-0780 and its investor relations email address is [email protected]. The official website for TRACON Pharmaceuticals is www.traconpharma.com. Learn More about contacing TRACON Pharmaceuticals investor relations.